- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00291200
Enhancing the Prospective Prediction of Psychosis
Przegląd badań
Status
Warunki
Szczegółowy opis
Psychosis is a serious mental condition in which a person momentarily loses contact with reality. People in a state of psychosis may experience hallucinations or delusional beliefs that make day-to-day functioning difficult. During the early development of psychosis, people undergo an initial change in mood, thinking, or behavior that may include making mistakes about smells, sounds, or sights; becoming easily distracted; and developing suspicions of others. These basic symptoms can be early warning signs of a brain disorder, including anxiety disorder, depression, or psychotic disorder. Basic symptoms may be due to a number of factors, including a reaction to stress or drugs or just a part of normal adolescence. To identify psychosis early and accurately, more information is needed on the initial stages, biological markers, and progression of psychosis. This study will gather information on the natural history of the basic symptoms of psychosis to identify factors that may affect the improvement or persistence of the symptoms.
Participation in this study will last up to 5 years. The initial screening visit will be used to determine whether a participant is eligible for the group displaying basic symptoms or the control group. Initial screening will include giving a blood sample for routine lab tests, a physical exam, a drug test, and questions about medical history and symptoms. All participants will then partake in baseline evaluations, which involve assessments concerning concentration, problem solving, memory, social skills, and ability to identify smells. Participants will also respond to questions about symptoms, school and social functioning, stressful situations, and family history of illnesses. The participants who meet the criteria for basic symptoms will attend monthly 1-hour follow-up visits for the first year of the study. During these visits, participants will be asked about the status of their basic symptoms and use of medications. For the second year of the study, follow-up visits will occur every 2 months, and for the third, fourth, and fifth years of the study, visits will be every 3 months. Repeat baseline assessments will occur every 6 months, with each assessment visit lasting about 5 hours. All participants will undergo endpoint evaluations that follow the same format as most baseline assessments. Participants who develop a psychotic disorder during the study will attend an additional follow-up visit 6 months after the endpoint evaluation to confirm diagnosis. Participants who decide that they no longer wish to attend regular study visits may be asked to participate in follow-up telephone interviews about their basic symptoms every 6 months.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Ontario
-
Toronto, Ontario, Kanada
- PRIME Clinic
-
-
-
-
Connecticut
-
New Haven, Connecticut, Stany Zjednoczone, 06519
- Prevention through Risk Identification Management and Education (PRIME) Clinic
-
-
North Carolina
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27599
- PRIME Clinic
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Meets modified criteria of prodromal syndromes (COPS) for schizophrenia prodrome or help-seeking control
Exclusion Criteria:
- History of psychosis
- Antipsychotic treatment in the month prior to study entry
- More than 16 weeks of lifetime antipsychotic treatment
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
---|
1
Participants with basic symptoms of psychosis
|
2
Control participants
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
---|---|
Information on the natural history of basic symptoms of psychosis
Ramy czasowe: Measured monthly during Year 1; every 2 months during Year 2; and every 3 months during Years 3, 4, and 5
|
Measured monthly during Year 1; every 2 months during Year 2; and every 3 months during Years 3, 4, and 5
|
Factors that may affect the improvement or persistence of basic symptoms of psychosis
Ramy czasowe: Measured monthly during Year 1; every 2 months during Year 2; and every 3 months during Years 3, 4, and 5
|
Measured monthly during Year 1; every 2 months during Year 2; and every 3 months during Years 3, 4, and 5
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Scott W. Woods, MD, Yale School of Medicine
- Główny śledczy: Jean Addington, PhD, University of Toronto
- Główny śledczy: Diana O. Perkins, MD, MPH, University of North Carolina
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- MH61282
- 5U01MH066160 (Grant/umowa NIH USA)
- DATR AD-P
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .